Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Flexion Therapeutics Inc | flxn-ex322_7.htm |
| EX-32.1 - EX-32.1 - Flexion Therapeutics Inc | flxn-ex321_9.htm |
| EX-31.2 - EX-31.2 - Flexion Therapeutics Inc | flxn-ex312_10.htm |
| EX-31.1 - EX-31.1 - Flexion Therapeutics Inc | flxn-ex311_6.htm |
| EX-21.1 - EX-21.1 - Flexion Therapeutics Inc | flxn-ex211_11.htm |
| EX-10.15 - EX-10.15 - Flexion Therapeutics Inc | flxn-ex1015_43.htm |
| EX-10.6 - EX-10.6 - Flexion Therapeutics Inc | flxn-ex106_42.htm |
| EX-4.5 - EX-4.5 - Flexion Therapeutics Inc | flxn-ex45_41.htm |
| 10-K - 10-K - Flexion Therapeutics Inc | flxn-10k_20191231.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-219099) and Form S-8 (Nos. 333-193907, 333-202957, 333-210111, 333-216615, 333-221373, 333-223532 and 333-229969) of Flexion Therapeutics, Inc. of our report dated March 12, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
|
/s/ PricewaterhouseCoopers LLP |
|
Boston, Massachusetts |
|
March 12, 2020 |